10 completed, 2 unknown, 1 recruiting. 13 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 10, Unknown 2, Recruiting 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Postmenopausal Osteoporosis: new trials by email Literature Review of Postmenopausal Osteoporosis trials Research Report on Postmenopausal Osteoporosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis Risk in Postmenopausal Females Blackcurrant (BC) extract, Placebo - Postmenopausal Osteoporosis, Gut Microbiome | Phase 1 | Recruiting | University of Connecticut | 159 | 2026-07-01 | 2026-07-23 |
| Comparing of the Pharmacokinetic, Safety and Immunogenicity of HS-20090-2 Injection and Prolia® in Healthy Adults HS-20090-2, Prolia - Postmenopausal Osteoporosis | Phase 1 | Unknown | Shanghai Hansoh Biomedical Co., Ltd | 174 | 2021-07-26 | 2021-08-25 |
| Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk blackcurrant (BC) extract - Postmenopausal Osteoporosis, Gut Microbiota | Phase 1 | Completed | University of Connecticut | 51 | 2021-07-20 | 2025-08-12 |
| Bioequivalence Study of SAL001 and FORSTEO in Healthy Chinese Adults SAL001, FORSTEO - Postmenopausal Osteoporosis | Phase 1 | Completed | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 64 | 2020-08-19 | 2021-02-10 |
| Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers Prolia®, CMAB807 - Postmenopausal Osteoporosis | Phase 1 | Completed | Shanghai Biomabs Pharmaceutical Co., Ltd. | 132 | 2019-07-01 | 2020-10-14 |
| Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Usability of Abaloparatide-solid Microstructured Transdermal System (sMTS) in Postmenopausal Women With Low Bone Mineral Density (BMD) abaloparatide-sMTS - Postmenopausal Osteoporosis | Phase 1 | Completed | Radius Health, Inc. | 22 | 2019-04-09 | 2023-11-22 |
| G56W1 in Women With Postmenopausal Osteoporosis rhPTH(1-34) 28.2μg, rhPTH(1-34) 56.5μg, teriparatide acetate(Teribone™) - Postmenopausal Osteoporosis | Phase 1 / Phase 2 | Unknown | Shenzhen Salubris Pharmaceuticals Co., Ltd. | 148 | 2018-10-01 | 2018-10-25 |
| A Study to Determine the Patient Preference Between Zosano Pharma Parathyroid Hormone (ZP-PTH) Patch and Forteo Pen ZP-PTH, FORTEO - Postmenopausal Osteoporosis | Phase 1 | Completed | Zosano Pharma Corporation | 24 | 2015-06-01 | 2016-08-23 |
| The Effects of Denosumab on the Pharmacokinetics (PK) of Midazolam Denosumab, Midazolam - Postmenopausal Osteoporosis | Phase 1 | Completed | Amgen | 30 | 2010-11-01 | 2018-08-07 |
| Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of PTH134 at Increasing Doses in Healthy Postmenopausal Subjects PTH134 - Postmenopausal Osteoporosis | Phase 1 | Completed | Novartis | 32 | 2008-05-01 | 2008-12-11 |
| Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women Oral salmon calcitonin, salmon calcitonin nasal spray - Postmenopausal Osteoporosis | Phase 1 | Completed | Novartis | 56 | 2006-10-01 | 2007-05-28 |
| Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation. Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg - Postmenopausal Osteoporosis, Postmenopause | Phase 1 | Completed | Wyeth is now a wholly owned subsidiary of Pfizer | 2006-09-01 | 2007-06-11 | |
| Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women Oral salmon calcitonin - Postmenopausal Osteoporosis | Phase 1 | Completed | Novartis | 86 | 2006-08-01 | 2006-12-13 |
Osteoporosis, Postmenopausal (13) · Osteoporosis (6) · Cardiovascular Diseases (1) · Hot Flashes (1)
Bone Diseases (13) · Bone Diseases, Metabolic (13) · Metabolic Diseases (13) · Musculoskeletal Diseases (13) · Nutritional and Metabolic Diseases (13) · Osteoporosis (7) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Denosumab (3) · Teriparatide (2) · salmon calcitonin (2) · Midazolam (1) · Parathyroid Hormone (1)
Novartis (3) · Shenzhen Salubris Pharmaceuticals Co., Ltd. (2) · University of Connecticut (2) · Amgen (1) · Radius Health, Inc. (1) · Shanghai Biomabs Pharmaceutical Co., Ltd. (1) · Shanghai Hansoh Biomedical Co., Ltd (1) · Wyeth is now a wholly owned subsidiary of Pfizer (1) · Zosano Pharma Corporation (1)
China (4) · United States (4) · Denmark (2) · Switzerland (1)
Dong Liu, PhD (1) · Hugh Coleman, DO (1) · Ock Chun, PhD (1) · Ock K Chun, PhD (1) · Weibo Xia, Prof. (1) · Xiuhua Ren, Master (1)
PMID 19055791, PMID 22289659, PMID 33638863, PMID 35140619, PMID 39019119
2025 (1)